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Abstract
Background: Intermittent preventive treatment in pregnancy with sulphadoxine-pyrimethamine
(IPTp-SP) has been adopted as policy by many countries in sub-Saharan Africa. However, data on
the post-implementation effectiveness of this measure are scarce.
Methods: Clinical and parasitological parameters were assessed among women delivering at a
district hospital in rural southern Ghana in the year 2000 when pyrimethamine chemoprophylaxis
was recommended (n  = 839) and in 2006 (n  = 226), approximately one year after the
implementation of IPTp-SP. Examinations were performed in an identical manner in 2000 and 2006
including the detection of placental Plasmodium falciparum infection by microscopy, histidine-rich
protein 2, and PCR.
Results: In 2006, 77% of the women reported to have taken IPTp-SP at least once (26%, twice;
24%, thrice). In 2006 as compared to 2000, placental P. falciparum infection was reduced by 43–57%
(P < 0.0001) and maternal anaemia by 33% (P = 0.0009), and median birth weight was 130 g higher
(P = 0.02). In 2006, likewise, women who had taken ≥ 1 dose of IPTp-SP revealed less infection and
anaemia and their children tended to have higher birth weights as compared to women who had
not used IPTp-SP. However, placental P. falciparum infection was still observed in 11% (microscopy)
to 26% (PCR) of those women who had taken three doses of IPTp-SP.
Conclusion:  In southern Ghana, placental malaria and maternal anaemia have declined
substantially and birth weight has increased after the implementation of IPTp-SP. Likely, these
effects can further be increased by improving IPTp-SP coverage and adherence. However, the
remnant prevalence of infection in women having taken three doses of IPTp-SP suggests that
additional antimalarial measures are needed to prevent malaria in pregnancy in this region.
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Background
Malaria in pregnancy is a major cause of maternal, foetal
and infant morbidity and mortality in sub-Saharan Africa.
Although frequently asymptomatic, consequences of Plas-
modium falciparum infection in pregnancy comprise
maternal anaemia, abortion, stillbirth, intrauterine
growth retardation, low birth weight (LBW), preterm
delivery, and up to 200,000 attributable infant deaths per
year [1-5]. Primiparae are particularly vulnerable as
immune mechanisms preventing placental sequestration
of pregnancy-specific parasite strains are weak or absent
[6,7].
Intermittent preventive treatment in pregnancy (IPTp)
denotes the administration of a curative dose of an anti-
malarial, commonly sulphadoxine-pyrimethamine (SP),
during routine antenatal care, irrespective of parasitaemia
being present or not. Given twice or thrice in the second
and third trimester of pregnancy, IPTp-SP has been shown
to be safe and to reduce placental malaria, maternal anae-
mia, and LBW [8-13]. IPTp with ≥2 doses of SP is currently
recommended by the World Health Organisation [14],
and has become policy in much of sub-Saharan Africa.
Nevertheless, coverage with IPTp still needs to be substan-
tially improved [15,16] and the effectiveness of IPTp may
be endangered by spreading and intensifying SP resistance
[17,18]. Although most clinical trials on IPTp-SP were
conducted in East Africa [8-10,19] the strategy was rapidly
adopted also in West Africa where its effectiveness is less
well documented [20]. Consequently, there is an urgent
need to monitor the post-implementation effectiveness of
IPTp in this region.
In southern Ghana, malaria in pregnancy and related
morbidity are frequent [21-23]. Ghana started the imple-
mentation of IPTp with three recommended doses of SP
at the end of 2004. In this country, SP achieves cure rates
within 28 days of follow-up of 14% and 11% in children
and pregnant women with uncomplicated malaria,
respectively [24,25]. Here, parasitological and clinical
parameters were compared among women delivering at
the Presbyterian Mission Hospital in Agogo, southern
Ghana, before (2000) and after (2006) the implementa-
tion of IPTp. In addition, these parameters were examined
with respect to the usage of IPTp among women deliver-
ing in 2006 and the number of doses taken.
Methods
Agogo is a community of some 30,000 inhabitants; sub-
sistence farming, trade and mining are the main income
sources in that region, and malaria is hyper- to holoene-
demic [26]. The characteristics of 839 women with live
singleton delivery recruited in 2000 have been described
in detail elsewhere [23]. Between April and June 2006, i.e.
during the rainy season, further 226 women with live sin-
gleton delivery were recruited. Both study protocols were
reviewed and approved by the Ethics Committee, Univer-
sity of Science and Technology, Kumasi, and all women
provided informed written consent. Sample collection as
well as clinical and parasitological examinations were per-
formed in an identical manner in 2000 and 2006 and
have previously been described [23]. In brief, women
were clinically examined and socio-demographic data
documented. Information on chemoprophylaxis or IPTp-
SP was collected from antenatal care cards and verified by
interviewing the women. Venous peripheral and placental
blood samples were collected into EDTA. Malaria para-
sites were counted microscopically on Giemsa-stained
thick blood films per 500 white blood cells (WBCs) for
peripheral samples and per 100 high-power fields
(1,000x) for placental samples. In the latter, the presence
of leukocyte-associated haemozoin was also recorded.
Slides were declared negative after having examined
microscopic fields corresponding to 500 WBCs, or 100
high-power fields. Based on placental thick blood film
microscopy, the stage of placental infection was catego-
rized [27] as early, only parasites visible; late, both para-
sites and pigment present; resolved, only pigment visible;
and none, neither parasites nor haemozoin present. In
placental samples, P. falciparum was additionally diag-
nosed by detection of histidine-rich-protein 2 (HRP2) and
nested PCR assays [28]. In 2000, HRP-2 was measured
using the ICT Malaria P.f/P.v (Becton Dickinson, Ger-
many) and, in 2006, using Malaria NOW P.f./P.v. (Inver-
ness Medical, Germany). Haemoglobin (Hb) was
measured by a HemoCue photometer (Ångelholm, Swe-
den) and anaemia and severe anaemia defined as Hb < 11
and < 7 g/dL, respectively. Fever was defined as an axillary
temperature ≥ 37.5°C and LBW as a birth weight < 2500 g.
For subsequent comparisons, three groups were formed,
i) 226 women recruited in 2006, ii) 839 women recruited
in 2000, and iii) 197 women who delivered in 2000 dur-
ing a period exactly matching the recruitment phase in
2006 (29.04.-27.06.). Geometric mean parasite densities
(GMPDs) and 95% confidence intervals (95%CIs) were
calculated. Continuous variables were compared between
groups by the non-parametric Mann-Whitney U and
Kruskal-Wallis tests as applicable, and proportions by χ2
test, Fisher's exact test and logistic regression models.
Results
The baseline characteristics of the three groups of deliver-
ing women are shown in Tables 1 and 2. In 2000, virtually
all women stated to have used pyrimethamine (25 mg
weekly) for chemoprophylaxis during pregnancy. In
2006, 76.5% (173/226) of women reported to have taken
IPTp-SP at least once, one women had used chloroquine
chemoprophylaxis, and 23.0% (52/226) neither IPTp nor
chemoprophylaxis. Eight percent of the women (17/208)Malaria Journal 2007, 6:144 http://www.malariajournal.com/content/6/1/144
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in 2006 reported to have slept under a bed net the night
before delivery.
As compared to 2000, women in 2006 more frequently
had attended antenatal care, tended to be older, less likely
to originate from Agogo, and more commonly to have a
school degree. Maternal anaemia was reduced by 33% in
2006, severe anaemia absent, and median Hb (+0.5 g/dL)
and median birth weight (+130 g) were higher. Fever
occurred more often in 2006 than in 2000 (Table 1). The
prevalence of microscopically confirmed placental parasi-
taemia was more than halved (reduction by 57%) in 2006
as compared to 2000, and parasite density reduced at bod-
erline statistical significance. Similar reductions in the
prevalence of infection were observed considering the
results of pigment detection (by 43%), HRP2 tests, and
PCR (both by 46%). The stage of placental infection,
peripheral blood film positivity and peripheral parasite
densisty were not significantly changed, however (Table
2). Comparing these parameters between women deliver-
ing in 2006 and women delivering during the matching
Table 1: Characteristics of women with live singleton delivery at Agogo Hospital, southern Ghana, in 2000 and 2006
Year of delivery
Parameter 2000 2000, matching 
dates subset
2006 2006 vs. 2000, P 2006 vs. 2000 
subset, P
No. 839 197 226 - -
Residence in Agogo (%) 48.9 50.3 42.5 0.09 0.13
Age (years; median, range) 25 (15–47)a 25 (16–42)b 26 (16–42) 0.12 0.31
Proportion without school degree (%) 15.4 (128/829) 13.8 (27/195) 10.4 (23/222) 0.06 0.27
Parity (median, range) 2 (1–11) 2 (1–9) 2 (1–11) 0.14 0.43
Primiparae (%) 36.5 (304/832) 34.2 (66/193) 32.7 0.29 0.75
Proportion caesarean section (%) 22.1 18.3 24.8 0.38 0.11
No. of ANC visits (mean, range) 3.9 (0–12) 3.9 (0–11) 4.5 (0–14) 0.01 0.047
Proportion with > 3 ANC visits 52.3 (429/821) 48.7 (93/191) 58.7 (131/223) 0.08 0.04
Birth weight (g; median, range) 2,950 (1,280–4,500)c 2,900 (1,450–4,350) 3,080 (1,600–5,460)d 0.02 0.0008
LBW (%) 16.0 (134/838) 19.3 12.4 (28/225) 0.19 0.05
Haemoglobin (g/dL; median, range) 11.5 (4.6–16.8) 11.7 (4.6–15.0) 12.0 (7.2–15.9) < 0.0001 0.04
Maternal anaemia (%) 35.2 33.0 23.5 0.0009 0.03
Severe anaemia (Hb < 7; %) 1.8 1.5 0 0.05 0.10
Fever (%) 2.8 (23/826) 1.5 (3/196) 6.6 0.006 0.01
ANC, antenatal care; LBW, low birth weight; a, n = 827; b, n = 192; c, n , = 838; d, n = 225
Table 2: Parasitological indices of delivering women at Agogo Hospital, southern Ghana, in 2000 and 2006
Year of delivery
Parameter 2000 2000, matching 
dates subset
2006 2006 vs. 2000, P 2006 vs. 2000 
subset, P
No. 839 197 226
Placental infection (%)
Microscopy 34.9 29.9 15.0 <0.0001 0.0002
Pigment 30.9 31.0 17.7 <0.0001 0.001
HRP2 40.8 38.6 22.1 <0.0001 0.0002
P C R 5 9 . 45 1 . 33 1 . 9<0.0001 <0.0001
Stage of placental infection
Resolved 17.9 (64/357) 28.1 (23/82) 27.7 (13/47)
Late 54.6 (195/357) 46.3 (38/82) 57.4 (27/47)
Early 27.5 (98/357) 25.6 (21/82) 14.9 (7/47) 0.10 0.31
Placental parasite density (GMPD, 95%CI) 0.78 (0.57–1.03) 0.61 (0.32–1.15) 0.31 (0.12–0.80) 0.06 0.23
Peripheral blood film positive (%) 19.0 11.2 14.6 0.13 0.29
Peripheral parasite density (GMPD, 95%CI) 558 (404–772) 506 (224–1142) 891 (366–2172) 0.24 0.39
HRP2, histidine rich protein 2, GMPD, geometric mean parasite density; 95%CI, 95% confidence intervalMalaria Journal 2007, 6:144 http://www.malariajournal.com/content/6/1/144
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period in 2000, basically the same results were seen
(Tables 1 and 2).
Stratifying by parity, improvements in haematological
and parasitological parameters in 2006 as compared to
2000 were found to be more pronounced in multiparae
than in primiparae (Table 3). In contrast, there was a con-
siderable reduction in the rate of LBW among primiparae
but hardly a change in multiparae. Adjusting the 2000
data set for the months of recruitment in 2006 diminished
these parity-dependent differences, particularly with
respect to placental infection (Table 3), whereas regard of
potential confounders (age, residence, antenatal care,
educational status) did not have such an effect.
Next, women delivering in 2000 were compared with the
small group of women delivering in 2006 who had not
taken IPTp. Placental P. falciparum infection was non-sig-
nificantly reduced by 12% to 17% in 2006 with the
exemption of microscopically proven parasitaemia which
dropped by 40% (P = 0.03; Tables 2 and 4). Birth weight
and Hb as well as the proportions of LBW and anaemia
were very similar in these two groups (Tables 1 and 4).
Lastly, clincial and parasitological parameters of women
delivering in 2006 were analysed according to the previ-
ous administration of IPTp (Table 4). All women previ-
ously on IPTp had attended antenatal care at least once,
but also 80% (41/51) of those who had not taken IPTp (P
< 0.0001). Overall, 23.5%, 26.5%, 26.1%, and 23.9% of
the women had received none, one, two, and three doses
of IPTp, respectively. The number of IPTp doses and ante-
natal care attendance were associated (Table 4). The pro-
portion of women having used IPTp was similar in
individuals from Agogo (79.2%) and elsewhere (74.6%; P
= 0.42) as were the number of doses taken (both groups,
median 2, range 1–3; P = 0.54). Primiparae (70.3%) and
multiparae (79.6%) did not differ significantly in the use
of IPTp (P = 0.12), or in the number of doses taken (both
groups, median 2, range 1–3; P = 0.42). The median ges-
tational age (range) at IPTp doses one, two, and three was
24 (16–39), 28 (18–38), and 32 (22–37) weeks, respec-
tively. The gestational week at the first IPTp administra-
tion was highest among women who had received one
dose only (28.5, 19–39), and lower in women who had
taken two (24, 16–32) or three doses (20, 16–24; P <
0.0001).
Overall, women who had received IPTp exhibited signifi-
cantly less placental malaria and maternal anaemia than
women who had not used IPTp; also, the former were
older and had higher Hb concentrations (Table 4). Para-
site densities did not differ between women with and
without previous IPTp (data not shown). In women with
three preceding doses of IPTp, birth weight and Hb con-
centrations were highest and anaemia least common.
However, there was no clear-cut trend for less morbidity
or placental malaria with increasing number of IPTp doses
administered (Table 4).
Discussion
In this observational study, women delivering at a district
hospital in rural southern Ghana after the implementa-
tion of IPTp-SP had significantly less placental malaria
and anaemia and babies of higher birth weight than six
years before when pyrimethamine chemoprophylaxis was
the common mode of malaria prevention. This is a sub-
stantial improvement which, however, cannot exclusively
be attributed to the implementation of IPTp since further
factors known to be or potentially involved, e.g. antenatal
care attendance, residence, and educational status, also
changed over time. A further limitation of the present
study is that malaria incidence or transmission intensity
in Agogo and surroundings could have declined between
Table 3: Clinical and parasitological indices in delivering women according to parity and year of delivery
Parameter Primiparae Multiparae
2000 2006 aOR (95%CI) P† 2000 2006 aOR (95%CI) P†
No. 304 74 528 152
Hb (g/dL; median, range) 11.4 (4.6–16.4) 11.6 (7.7–14.8) - 0.11 11.6 (4.7–16.8) 12.1* (7.2–15.9) - 0.08
Maternal anaemia (%) 38.5 35.1 0.74 (0.37–1.46) 0.38 33.5 17.8* 0.55 (0.31–0.96) 0.04
Birth weight 
(g; median, range)
2,785 (1,280–4,000) 2,900* (1,600–4,600) - 0.006 3,020 (1,500–4,500) 3,130 (1,650–5,460) - 0.02
LBW (%) 26.0 16.2 0.41 (0.19–0.93) 0.03 10.2 (54/527) 10.6 (16/151) 0.82 (0.39–1.72) 0.60
Placental infection (%)
Microscopy 46.1 25.7* 0.44 (0.22–0.90) 0.02 28.4 9.9* 0.39 (0.20–0.76) 0.006
Pigment 42.4 27.0* 0.44 (0.22–0.90) 0.02 24.2 13.2* 0.49 (0.26–0.91) 0.02
HRP2 50.7 39.2 0.57 (0.29–1.12) 0.10 35.2 13.8* 0.35 (0.19–0.63) 0.0005
PCR 65.1 44.6* 0.46 (0.23–0.91) 0.03 56.4 25.7* 0.41 (0.25–0.68) 0.0005
aOR, odds ratio adjusted for months of recruitment in 2006; 95%CI, 95% confidence interval; *, bivariate comparison 2000 vs. 2006; P < 0.05 †, P value 
derived from logistic regression models, or from multiple linear regression models (coding: 0, 2000; 1; 2006; and 0, non-matching recruitment period; 
1, matching recruitment period)Malaria Journal 2007, 6:144 http://www.malariajournal.com/content/6/1/144
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2000 and 2006. The implementation of e.g. artemisinin-
based combination treatment in Ghana and other inter-
ventions might have led to a reduced malaria transmis-
sion and burden of disease. However, no dependable data
are available to substantiate this. Though, in women in
2006 who did not take IPTp, the prevalence of placental
infection (but not of LBW or anaemia) was lower than in
2000. However, this reduction did not have the magni-
tude seen in the 2006 group overall or among women
having used IPTp. Moreover, comparing women deliver-
ing in 2006 with and without previous IPTp points into
the same direction suggesting that IPTp in fact has mark-
edly reduced the burden of malaria in pregnancy and
related consequences. Still, 32% of women delivering
after the implementation of IPTp were found to be P. fal-
ciparum  infected, and maternal anaemia and LBW
occurred in 24% and 12%, respectively, with higher fig-
ures among primiparae. This likely results from both,
incomplete IPTp coverage and a remnant burden of dis-
ease which cannot further lowered even by complete cov-
erage with this one measure of malaria control.
Data on IPTp-SP in West Africa are rare. In Mali and as
compared to chloroquine chemoprophylaxis, 2-dose
IPTp-SP significantly reduced the risks of placental parasi-
taemia, maternal anaemia, and LBW [11]. In a smaller
trial from Nigeria, IPTp-SP was superior to pyrimeth-
amine chemoprophyaxis in the prevention of parasitae-
mia and anaemia which was confirmed and
complemented by a beneficial effect on birth weight in a
recent observational study [29,30]. In Burkina Faso, the
implementation of IPTp-SP in one district reduced placen-
tal parasitaemia and LBW, the latter, however, only when
three doses had been taken [31]. Lastly, in The Gambia,
IPTp-SP benefited multigravidae only when not protected
by a bednet [32]. Altogether, these data show that IPTp-SP
in West Africa is superior to available chemoprophylactic
approaches but the effects achieved vary geographically
and with the characteristics of the target population.
In the present study, only a quarter of delivering women
had received all three recommended doses of IPTp-SP,
and only half had taken two or more doses. Antenatal care
attendance and both, use of IPTp-SP and number of doses
were associated illustrating that efforts to promote antena-
tal care will likely be paralleled by increasing IPTp cover-
age, and, consequently, lead to even more pronounced
effects than observed here. At Agogo hospital, the first
dose of IPTp-SP was taken at a median gestational age of
24 weeks, i.e. roughly at halftime of pregnancy. While
observed treatment during antental care visits is a major
asset of IPTp, its comparatively late utilisation during
pregnancy in general is a major drawback. Malaria early in
pregnancy not only contributes to abortion but also to
intrauterine growth retardation and LBW [2]. So far, it is
unknown whether the pathophysiological changes and
foetal damage induced by infections in early pregnancy
are reversible and, thus, the extent of morbidity due to the
relatively late initiation of IPTp cannot be estimated. Edu-
cation and information campaigns flanking IPTp as well
as community-based delivery systems may promote early
initiation of IPTp and also improve access, attendance and
adherence to the programme [33,34]. Further measures of
malarial control, however, are needed to cover the vulner-
able period of early pregnancy. Insecticide treated nets
Table 4: Clinical and parasitological indices in delivering women in 2006 according to intermittent preventive treatment in pregnancy
Parameter Intermittent preventive treatment in pregnancy
Nonea All One dose Two doses Three doses
No. 53 173 60 59 54
Age 24 (17–42) 27 (16–41)* 26 (16–40) 26 (16–40) 28 (16–41)*
P r i m i p a r a e  ( % ) 4 1 . 53 0 . 13 5 . 02 7 . 12 7 . 8
Proportion with > 3 ANC visits (%) 35.3 (18/51) 65.7* (113/172) 41.7 65.5* (38/58) 92.6*
Birth weight (g; median, range) 2,900 (1,820–4,000) 3,100 (1,600–5,460) 3,025 (2,200–5,460) 3,100 (1,600–4,250) 3,125 (2,030–4,100)
LBW (%) 15.4 (8/52) 11.6 10.0 15.3 9.3
Hb (g/dL; median, range) 11.5 (7.2–14.5) 12.1 (7.7–15.9)* 12.1 (8.4–15.6)* 11.9 (7.7–14.4) 12.4 (9.3–15.9)*
Maternal anaemia (%) 39.6 18.5* 16.7* 27.1 11.1*
Fever (%) 1.9 8.1 13.3* 5.1 5.6
Placental infection (%)
Microscopy 20.8 13.3 13.3 15.3 11.1
P i g m e n t 2 6 . 41 5 . 01 5 . 01 5 . 31 4 . 8
HRP2 35.8 17.9* 13.3* 22.0 18.5*
PCR 49.1 26.6* 21.7* 32.2 25.9*
a, includes one women with previous chloroquine chemoprophylaxis; b, median, range; *, as compared to women without IPTp, P < 0.05Malaria Journal 2007, 6:144 http://www.malariajournal.com/content/6/1/144
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(ITNs) are a suitable and effective option [35], but the bed
net coverage rate (8%) seen in this study is far too low.
Primiparae in 2006 showed an only slightly lower rate of
IPTp usage than multiparae arguing for a similar level of
information and acceptance among women of different
parities. Elsewhere, however, primiparity, young age, and,
thereby, a presumed low level of malaria-related knowl-
edge, might be an obstacle in taking up interventions such
as IPTp. IPTp should be most effective in primiparae in
whom antimalarial immunity is lowest and infection rates
are highest [1,4,6,7,23]. In fact, data from East Africa and
from multigravidae in The Gambia point into this direc-
tion [8,32]. Adjusting for the recruitment period, the
reductions in placental malaria observed between 2000
and 2006 were similar in primi- and multiparae but the
the reduction in maternal anaemia was significant only in
the latter. The proportion of LBW, in contrast, declined
significantly only in primiparae. Further adjustment for
potential confounders did not fundamentally change
these findings. These parity-dependent differences could
reflect a differential effect of reducing the prevalence of
malaria: in multiparae, increasing Hb concentrations
might be the most visible sign of improved malaria pre-
vention whereas the contribution of malaria to LBW is
comparatively small [36]. In fact, the rate of LBW among
multiparae in this study closely resembles the figure
among African Americans [37]. In contrast, in primiparae
the proportion of malaria-attributable LBW is larger than
in multiparae [36], and IPTp-SP thus can achieve a greater
extent of LBW reduction. So far, it is unclear why primi-
parae did not benefit from IPTp in haematological terms.
Beyond a comparatively small sample size, this could
stem from the still high prevalence of placental malaria in
this group, or alternatively, reflect the importance of
other, non-malaria causes of anemia. Such could involve
e.g. iron deficiency which has previously been observed in
only 5–18% of pregnant women in Agogo [22] and HIV
infection, which occurs among 3% of pregnant women in
Ghana [38].
No straightforward trend for less malaria, anaemia or
LBW with increasing number of IPTp doses was observed
in this study. Stratification into relatively small subgroups
might be one reason. The sample size also impeded a
meaningful analysis of the effects by parity and of the time
when the last IPTp dose was given. The latter has been
shown to unevenly influence the risk reduction of placen-
tal malaria in Kenya [39]. Selection of drug-resistant para-
sites during the course of IPTp-SP could also be involved
but, so far, it is not understood whether and to which
extent this occurs. In children, a substantial increase in the
proportion of resistant parasites has been observed within
weeks after preventive SP treatment [40].
Drug resistance might also be responsible for the preva-
lence of 26% of placental P. falciparum infection observed
in women who had taken all three doses of IPTp-SP.
Already in 2000, 52% of placental P. falciparum isolates
from Agogo hospital exhibited the triple dihydrofolate
reductase mutation (Ile51+Arg59+Asn108) [41] which in
Ghanaian children increases the risk of SP treatment fail-
ure ten-fold [42]. Preliminary data from a subset of the
study participants indicate that this figure has increased to
more than 75% in 2006. While these findings support the
utilisation of preventive approaches in addition to IPTp-
SP they also question the useful lifespan of IPTp-SP in the
study area and support the urgent evaluation of alterna-
tive drugs.
Conclusion
In rural southern Ghana, the prevalences of placental
malaria and of maternal anaemia have substantially been
reduced following the implementation of IPTp-SP, and
birth weight has increased. These achievements may be
improved by increasing the proportion of pregnant
women receiving IPTp-SP via enforced antenatal care serv-
ices and information campaigns. Even then, however, a
remnant prevalence of malaria in pregnancy will probably
remain necessitating the implementation of further
means of preventing malaria in pregnancy. Meanwhile,
alternative options to SP in IPTp should urgently be eval-
uated.
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